Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
Phase 3
Completed
- Conditions
- HypercholesterolemiaCarotid Artery Stenosis
- Interventions
- Registration Number
- NCT00654394
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Fasting blood low density lipoprotein cholesterol level as defined by the protocol
- Diagnosed carotid arterial stenosis
Exclusion Criteria
- The use of lipid lowering drugs or dietary supplements after Visit 1.
- Heavy or total occlusion of the carotid artery or recent stroke
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Rosuvastatin -
- Primary Outcome Measures
Name Time Method Changes in carotid wall volume as measured by MRI scan At 40 weeks and 104 weeks
- Secondary Outcome Measures
Name Time Method Safety: adverse events & abnormal laboratory markers 2 weekly for first 4 weeks then 4 weekly Other changes in the structure and composition of the carotid arterial wall as defined in the protocol. At 40 weeks and 104 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which rosuvastatin inhibits HMG-CoA reductase in hypercholesterolemia?
How does the efficacy of high-dose rosuvastatin compare to standard statins in reducing carotid atheroma progression?
Which biomarkers correlate with carotid stenosis response to statin therapy in NCT00654394 trial participants?
What are the long-term adverse event profiles of ZD4522 in moderately hypercholesterolemic populations?
How do combination therapies with rosuvastatin and PCSK9 inhibitors impact atherosclerosis progression in clinical trials?